Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

Hair loss treatments, such as Dutasteride, Minoxidil, and Finasteride. Advice is given to give the medications time to work and to consider a Hair Transplant in order to fill any gaps caused by continuing hair loss.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

A 22-year-old male has been experiencing hair thinning since 18 and was prescribed 50mg oral spironolactone for hair loss and high blood pressure, despite inquiring about finasteride. A reply suggests that spironolactone is less effective than finasteride and minoxidil for hair loss and recommends seeking a second medical opinion.

A user considered restarting finasteride for hair loss despite past side effects, which worried their girlfriend. Others suggested alternatives like topical treatments or lower doses and emphasized prioritizing well-being and relationship stability.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

A 19-year-old is frustrated with doctors giving misleading information about hair loss treatments, specifically finasteride and minoxidil. They plan to self-administer finasteride due to concerns about side effects and lack of supportive medical guidance.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hair follicles is considered a potential solution, but it's currently not feasible.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

Different minoxidil formulations affect hair growth and side effects. Higher propylene glycol and pH levels improve effectiveness but can cause scalp irritation.

The conversation discusses finasteride for hair loss, especially among those with a history of depression. Users shared mixed experiences, with some reporting no issues and others experiencing worsened depression.

A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

User discusses Pyrilutamide's effectiveness for hair loss, needing more time for results. Others suggest waiting 6-12 months and ask about side effects.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

Serum DHT levels and their variations when using dutasteride for hair loss treatment.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about seeking alternatives to finasteride for hair loss treatment due to concerns about sexual side effects, with pyrilutamide mentioned as a potential alternative.

A user shared their hair loss treatment plan using Revita tablets, Sulforaphane, Minoxidil, and microneedling, avoiding finasteride due to side effects. Replies suggest that without finasteride, the plan is unlikely to be effective, and recommend either using finasteride or shaving their head.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.

The user lost hair progress while in jail due to stopping treatments like oral dutasteride, topical applications, and ketoconazole shampoo. They plan to restart their regimen and hope to recover in about 18 months.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.